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Abstract
Human lungs contain secretory leukocyte protease inhibitor (SLPI), elafin and its biologically active precursor trappin-2 (pre-
elafin). These important low-molecular weight inhibitors are involved in controlling the potentially deleterious proteolytic
activities of neutrophil serine proteases including elastase, proteinase 3 and cathepsin G. We have shown previously that
trappin-2, and to a lesser extent, elafin can be linked covalently to various extracellular matrix proteins by tissue
transglutaminases and remain potent protease inhibitors. SLPI is composed of two distinct domains, each of which is about
40% identical to elafin, but it lacks consensus transglutaminase sequence(s), unlike trappin-2 and elafin. We investigated the
actions of type 2 tissue transglutaminase and plasma transglutaminase activated factor XIII on SLPI. It was readily covalently
bound to fibronectin or elastin by both transglutaminases but did not compete with trappin-2 cross-linking. Cross-linked
SLPI still inhibited its target proteases, elastase and cathepsin G. We have also identified the transglutamination sites within
SLPI, elafin and trappin-2 by mass spectrometry analysis of tryptic digests of inhibitors cross-linked to mono-dansyl
cadaverin or to a fibronectin-derived glutamine-rich peptide. Most of the reactive lysine and glutamine residues in SLPI are
located in its first N-terminal elafin-like domain, while in trappin-2, they are located in both the N-terminal cementoin
domain and the elafin moiety. We have also demonstrated that the transglutamination substrate status of the cementoin
domain of trappin-2 can be transferred from one protein to another, suggesting that it may provide transglutaminase-
dependent attachment properties for engineered proteins. We have thus added to the corpus of knowledge on the biology
of these potential therapeutic inhibitors of airway proteases.
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Introduction
A characteristic of inflammation is the release of serine
proteases (NSPs) from the azurophil granules of activated
neutrophils. These enzymes, including leukocyte elastase
(HNE), proteinase 3 (Pr3) and cathepsin G (CatG), are involved
in the proteolytic degradation of extracellular matrix proteins like
elastin. They are therefore believed to play a key role in
inflammatory tissue-destroying diseases of the lungs, such as
chronic obstructive pulmonary disease (COPD), acute lung injury
and cystic fibrosis (see [1] for a review). The activities of NSPs in
the human lung are mainly regulated by endogeneous protease
inhibitors like the serpin a1-PI and canonical inhibitors belonging
to the chelonianin family of protease inhibitors. This latter family,
assigned to Family I17 Clan IP in the MEROPS database
(http://merops.sanger.ac.uk), includes secretory leukocyte prote-
ase inhibitor (SLPI), elafin and its precursor trappin-2 (or
pre-elafin) [2] from which elafin is proteolytically released,
possibly by mast cell tryptase [3]. SLPI is a potent inhibitor of
leukocyte elastase and cathepsin G, whereas elafin and trappin-2
preferentially target leukocyte elastase and proteinase 3 (see [2]
for a review). Trappin-2 (95 residues), elafin (57 residues) and
SLPI (107 amino acids) all have structurally homologous WAP
(whey acidic protein) domains that each contain four disulphide
bonds, and are responsible for their inhibitory activity. Trappin-2
and elafin each contain one WAP domain while SLPI has two.
The N-terminal part of trappin-2 or cementoin domain [4] has a
unique cysteine-free sequence of 38 residues containing five
repeated motifs conforming to the consensus sequence GQDPVK
and thought to be transglutaminase substrates [4]. This finding
led to the hypothesis that trappin-2 could be covalently anchored
at its site of action, probably by transglutaminase-catalysed cross-
linking to extracellular matrix proteins [4]. Indeed, transgluta-
minase-2 (TGase), which is ubiquitously expressed in cells and is
secreted into the extracellular space [5], mediates the cross-
linking of trappin-2 to human epidermis proteins both in vitro and
in vivo [6]. Other in vitro studies have reported that trappin-2 is an
efficient TGase substrate, as it can be cross-linked to laminin [4],
elastin [7], fibronectin and other extracellular matrix (ECM)
proteins [8].
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mucous epithelium by Western blotting. But their apparent Mr
was much higher (,50 kDa) than expected (,6–12 kDa),
suggesting that they were cross-linked to ECM proteins [4].
Another study by Steinert and Marekov [9] identified several
proteins from the human stratum corneum that were cross-linked
by transglutaminases, including trappin-2 and to a lesser extent
elafin. They were mostly conjugated to loricrin, accounting for
about 6% of all the protein components of the cornified cell
envelope. Besides this structural role of trappin-2/elafin engaged
in protein-protein cross-links with various ECM proteins, the
biological role of conjugated inhibitors is not yet clear. The
covalent attachment of trappin-2 to protease-sensitive proteins
could be essential for protecting them from proteolytic degrada-
tion by neutrophil elastase or proteinase 3, both inhibited by
trappin-2 and elafin. Recent research in our laboratory has shown
that trappin-2 conjugated to fibronectin by transglutaminase-2
(TGase) is almost as active a protease inhibitor as soluble trappin-2
[8], thus confirming the defence-assistance role of anchored
trappin-2 originally proposed by Nara et al. [4]. This capacity of
trappin-2 and its genetically modified variants [10] to become
immobilized on ECM proteins in an interesting property in the
context of their possible use as aerosol-delivered anti-inflammatory
therapeutic agents for treating lung diseases. Such cross-linked
inhibitors could have longers half-lives at inflammatory sites than
the soluble proteins.
SLPI does not have any consensus transglutaminase substrate
sequence(s) but being homologous to trappin-2/elafin, we
investigated whether it could be a transglutaminase substrate.
We have now demonstrated that SLPI is readily cross-linked to
fibronectin and elastin by tissue transglutaminase-2 and plasma
factor XIIIa. And the covalently bound SLPI retains its ability to
inhibit neutrophil elastase (HNE) and cathepsin G (CatG).
Further, to gain mechanistic insight into the sequence and
structural determinants that allow transglutaminases to cross-link
these inhibitors, we used mass spectrometry to identified a set of
reactive glutamine and lysine residues in trappin-2, elafin and
SLPI that are targeted by transglutaminase-2.
Results
TGase- and factor XIIIa-directed incorporation of dansyl-
cadaverine and peptide substrates into elafin, trappin-2
and SLPI
We performed transglutamination assays to determine whether
the lysine or glutamine residues in elafin and trappin-2 are the
primary targets in transamidation reactions catalyzed by TGase
or FXIIIa. We used labelled primary amine dansyl-cadaverin
(DsC), which is widely used in transamidation assays because it
mimics a lysine side-chain, or three glutamine-containing
peptides. The peptide TGS1 with the sequence PGGQQIV is
derived from fibronectin [11] while TGS2 (HQSYVDPWM-
LDH) and TGS3 (DQMMLPWPAVAL) have been shown by
phage display to be efficient transglutaminase substrates; TGS2 is
selective for TGase and TGS3 for FXIIIa [12]. Elafin readily
formed complexes with molecular weights of about 12 kDa or
.17 kDa, as assessed by Western blotting, in the presence of
TGase (Fig. 1). Thus elafin is a transglutaminase substrate for
itself, with cross-linking through isopeptide bonds formed
between two or more elafin molecules. Adding DsC or
glutamine-containing peptides (TGS1, TGS2, TGS3) to the
incubation mixture almost totally inhibited the formation of
elafin-elafin complexes, even with TGS3, which is supposed to be
a poor substrate for TGase. This indicates that elafin contains
both reactive lysine and glutamine residues that participate in the
formation of isopeptide bonds and that these residues of elafin are
less efficient TGase substrates than are DsC, TGS1, TGS2 or
TGS3. Hence, TGase targets these small molecules rather than
elafin in the transamidation reaction.
We observed similar results with trappin-2 as a TGase substrate.
Cross-linking between trappin-2 molecules was inhibited by
TGS1, TGS2 and TGS3 peptides. But, in contrast to elafin,
inhibition was not total, suggesting that the additional Lys residues
in the cementoin domain of trappin-2 also served as TGase
substrates even in the presence of peptide substrates. Complex
formation was also inhibited by DsC (Fig. 1). However, the
formation of complexes with different molecular weights indicates
that cross-linking occurred through alternative transglutamination
sites when DsC was included in the reaction mixture. As TGS2
and TGS3 have been reported to be poor glutamine donor
substrates when reacted with the trappin-2-derived peptide
GQDPVK [12], we believe that other Lys residues in elafin or
trappin-2, including that of the AQEPVK motif at the N-terminus
of elafin, serve as acyl acceptors in transamidation reactions
involving elafin or trappin-2.
Figure 1. TGase-mediated incorporation of DsC and peptides
substrates in elafin, trappin-2 and SLPI. Each inhibitor
(1.2610
25 M) was incubated with TGase (1.25610
27 M) for 1 h at
37uC either alone (lane #2), with dansyl-cadaverin (DsC) (2 mM), or with
the glutamine-containing peptides TGS1, TGS2 and TGS3 (2.4 mM
each). Products were separated by high resolution 16% SDS-PAGE
electrophoresis and detected by Western blotting using primary
antibodies specific for each inhibitor and peroxidase-labelled secondary
antibodies. The right-hand lane in each panel contains molecular mass
standards.
doi:10.1371/journal.pone.0020976.g001
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substrate in vitro. Unlike trappin-2, SLPI does not contain motifs
containing the consensus sequence GQDPVK that has been
reported to be a substrate for tissue transglutaminases [13].
However, the N-terminal domain of SLPI contains a similar motif
having the W30QCPGK35 sequence, whose Gln and/or Lys
residues could be a TGase target. SLPI readily formed complexes
larger than 17 kDa in the presence of TGase, as indicated by SDS-
PAGE analysis (Fig. 1). This suggests that TGase catalysed the
cross-linking of two SLPI molecules. We confirmed the presence of
reactive glutamine and lysine residues in SLPI by incubating SLPI
with DsC or glutamine-containing peptides. As with elafin and
trappin-2, DsC and the peptides TGS1, TGS2, TGS3 all inhibited
the TGase-catalysed formation of SLPI complexes. Thus SLPI is a
TGase substrate for TGase and contains both reactive Gln and
Lys residues that can cross-link SLPI, DsC or Gln-containing
peptides.
We repeated these experiments on elafin, trappin-2 and SLPI
with FXIIIa as the transglutaminase, to determine the effects of
DsC and Gln-containing peptides. Elafin and trappin-2 may be
substrates of FXIIIa in vitro since they both formed high molecular
weight complexes when incubated with this enzyme (Fig. 2), as we
observed previously [8]. Elafin formed only one additional
molecular form, in contrast to its reaction with TGase, perhaps
because it has fewer transglutamination sites for FXIIIa. DsC,
TGS2 and TGS3 inhibited the transglutamination of elafin and
trappin-2 to themselves, but TGS1 did not. This indicates that
TGS1 is not a substrate for FXIIIa and that TGS2, which has
been reported to be selective for TGase [12], may also be an
FXIIIa substrate. This also confirms that elafin and trappin-2
contain both reactive Gln and Lys residues that are substrates for
tranglutaminases. FXIIIa catalysed the cross-linking of SLPI to
form complexes .17 kDa, and this complex formation was
slightly inhibited by DsC, TGS1 and TGS3 but not by TGS2.
Cross-linking of trappin-2 and SLPI to different target
residues on fibronectin and elastin
We and others have demonstrated that elafin and trappin-2 can
be covalently bound to fibronectin, elastin and other extracellular
matrix proteins in a reaction catalysed by a tissue transglutamin-
ase. Although SLPI is similar to elafin and trappin-2, there have
been no published reports of its capacity to be a transglutaminase
substrate. However, it does become associated with elastin fibers in
vivo by a yet unknown mechanism [14,15], which could involve
transglutamination. We assessed the transglutamination of SLPI
by incubating SLPI with fibronectin or elastin plus the enzymes
TGase or FXIIIa. SLPI readily formed high-molecular weight
complexes of about 250 kDa with both fibronectin and elastin
(Fig. 3). Since elafin/trappin-2 and SLPI can be transglutaminated
to the same substrates, we next performed transglutamination
assays in which SLPI and trappin-2 competed for TGase-catalysed
binding to fibronectin or elastin. The SLPI concentration was kept
constant and the trappin-2 concentrations were increased in a
reaction mixture containing fibronectin or elastin plus TGase.
Western blotting analysis indicated that the binding of SLPI to
fibronectin or elastin remained unchanged while the formation of
complexes involving trappin-2 increased with the trappin-2
concentration (Fig. 3) up to a 2.5 fold molar excess of trappin-2
over SLPI. Similar results were obtained using FXIIIa as a
transglutaminase (not shown). Thus trappin-2 and SLPI are not
mutually exclusive in their transglutaminase-mediated binding to
extra cellular matrix proteins.
Protease inhibitory activity of SLPI cross-linked to
fibronectin or elastin by transglutamination
We have shown that elafin and trappin-2 covalently bound to
fibronectin by TGase are still active protease inhibitors [8],
although they associate with their target proteases (HNE and Pr3)
more slowly than do the soluble inhibitors, probably because of
their immobilization. Because both the elafin-like domains of SLPI
contain many Gln and Lys residues that are potential transglu-
taminase targets, the question arose whether cross-linking of SLPI
onto fibronectin or elastin affects its inhibitory properties, bearing
in mind that only SLPI domain 2 (SLPI2) inhibits the target
neutrophil proteases, HNE and CatG [16,17]. Fibronectin or
elastin was first adsorbed onto high-adsorption ELISA plates and
then SLPI was conjugated by TGase. We then used the same
enzyme-based assay as that previously described [8] to measure
the residual proteolytic activity of HNE or CatG in the presence of
SLPI conjugated by TGase to immobilized fibronectin or elastin.
We postulated that transglutamination involved SLPI1 rather than
SLPI2 because SLPI domain 1 (SLPI1) has a sequence motif
W30QCPGK35 that is similar to the GQDPVK transglutaminase
substrate motif (vide ante) and because it has more Gln and Lys
residues (3 Gln, 9 Lys) than does SLPI2 (2 Gln, 6 Lys). We tested
this hypothesis by comparing the inhibitory properties of cross-
linked full-length SLPI with those of cross-linked SLPI2 and Cem-
SLPI2, a protein in which SLPI2 is fused at its N-terminal moiety
to the cementoin domain of trappin-2, which has been reported to
contain the main transglutamination sites in trappin-2 [4,13]. Full-
Figure 2. FXIIIa-catalysed incorporation of DsC and peptides
substrates in elafin, trappin-2 and SLPI. Conditions were the same
as in Fig. 1 except that FXIIIa was the transglutaminase.
doi:10.1371/journal.pone.0020976.g002
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and its capacity to inhibit HNE was about 95% of the control
(Fig. 4). SLPI was less active (about 60%) when it was conjugated
to elastin. TGase-conjugated trappin-2 behaved similarly, suggest-
ing that elastin is a poorer TGase substrate than is fibronectin, as
already mentioned for peptides TGS1, TGS2 and TGS3. Cross-
linked SLPI2 was a far less potent inhibitor (<40% inhibition)
than SLPI, while Cem-SLPI2 conjugated to fibronectin appeared
to be a potent inhibitor of HNE (<90%). The same tendency was
observed using CatG as a target enzyme except that immobilized
trappin-2 did not inhibit CatG as expected (Fig. 4). Because SLPI2
and Cem-SLPI2 have the same inhibitory potency as SLPI
(Ki=5 610
211 M for SLPI2-HNE, 2.6610
210 M for SLPI2-CatG,
2.7610
211 M for Cem-SLPI2/HNE, 7610
210 M for Cem-
SLPI2-CatG), differences in inhibitory activities of cross-linked
inhibitors are mainly related to the efficiency of the transglutami-
nation reaction in which they are involved. Inhibitors cross-linked
by FXIIIa appeared to be less active inhibitors, probably as a
consequence of being less efficiently transglutaminated by FXIIIa
compared to TGase, using similar enzyme concentrations. Thus,
these results support our hypothesis that most of the transgluta-
mination sites of SLPI are located in SLPI1 rather than in the
inhibitory SLPI2 domain. We have also shown that the cementoin
domain of trappin-2 can almost fully or partially restore,
depending on the substrate, the transglutamination potential of
SLPI when fused to SLPI2.
Identification of TGase-reactive glutamine and lysine
residues in elafin, trappin-2 and SLPI by mass
spectrometry
We used two approaches to identify the reactive glutamine and
lysine residue(s) within each inhibitor that reacted with TGase. In
the first, we labelled each inhibitor with either DsC or the
fibronectin-derived peptide PGGQQIV (TGS1) using TGase and
then performed MALDI-TOF mass spectrometry analysis of crude
reaction products or of fragments produced by trypsin digestion of
cross-linked products. MALDI-TOF analysis of the non-digested
reaction products (not shown) revealed that SLPI and trappin-2
were substituted by either one, two or three DsC or TGS1
peptides. In the SLPI-TGS1-TGase mixture, we also observed a
fourth form which most probably contained four TGS1-derived
Lys. With elafin reacting with either DsC or TGS1, we observed
one major peak in the MALDI-TOF spectrum suggesting that the
mono-substituted form of elafin was likely to be predominant in
the reaction mixture. All these molecular forms were already
observed after 5 min. incubation with TGase and progressively
increased as a function of time while the native form decreased at
the same time. But no additional m/z signals appeared up to 1 h
incubation with TGase. Since MALDI-TOF analysis do not allow
accurate quantitations, we did not attempt to determine the exact
proportion of each form. Altogether these results suggest that each
inhibitor is present in several molecular forms reflecting the fact
that a restricted, preferential set of Gln or Lys residues are targeted
by TGase.
In order to identify these TGase-sensitive residues, we then
performed tryptic peptide map MALDI-TOF analysis (Fig. 5).
Because these cationic inhibitors contain many Arg and Lys
residues, the tryptic fragments obtained were small enough for
direct analysis. The MS data were matched automatically to a
database containing the trappin-2, elafin and SLPI protein
sequences using the Peptide Mass Fingerprint search option of
the MASCOT server software. Sequence coverage for MS analysis
of DsC-derived fragments was 100% for trappin-2 and elafin, 90%
for SLPI; it was 92% for trappin-2 fragments modified by TGS1,
100% for elafin fragments and 96% for SLPI fragments. Reactive
glutamine and lysine residues were identified from the altered mass
of the fragments containing DsC-derived glutamine (+318 Da) or
TGS1-lysine (+681.38 Da) and the release of an ammonia
molecule (17.03 Da) for each e-(c-glutamyl)-lysine cross-link
formed by TGase catalysis (Table 1). Some tryptic fragments
Figure 3. Influence of trappin-2 on the transglutamination-
mediated binding of SLPI to fibronectin and elastin. (A) SLPI was
cross-linked to fibronectin or to elastin by TGase or by FXIIIa. SLPI
(3610
26 M) was incubated with fibronectin (3 mg) or elastin (5 mg) plus
TGase (1.25610
27 M) or FXIIIa (10
26 M) for 2 h at 37uC. Cross-linked
products were separated by SDS-PAGE in 10% Tris-Glycine and detected
by Western blotting with anti-SLPI antibodies. (B, C) Competition
between SLPI and trappin-2 for their transglutaminase-catalysed
incorporation into fibronectin (B) or elastin (C). SLPI (3610
26 M) was
incubated for 2 h at 37uC with trappin-2 (3610
27 to 7610
26 M),
fibronectin (3 mg) or elastin (5 mg) and TGase (1.25610
27 M). The
products were separated in parallel runs on two 10% SDS-PAGE gels
and detected by Western blotting using anti-SLPI antibodies for the first
gel and anti-trappin-2 antibodies for the second gel. The SLPI control
and trappin-2 control refer to the TGase-catalysed cross-linking of SLPI
and trappin-2 alone to either fibronectin or elastin. Similar results were
obtained using FXIIIa (not shown) indicating that the transglutaminase-
catalysed conjugation of SLPI and trappin-2 to either fibronectin or
elastin do not compete; each inhibitor has its own transglutamination
sites on these extracellular matrix proteins.
doi:10.1371/journal.pone.0020976.g003
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substituted by one or more TGS1 peptides so that non-ambiguous
identification of reactive lysines by inference was not possible in
these conditions. These peptides were further fragmentated and
analyzed by nanospray LC-MS/MS (Fig. 6). Peptides were
considered to be identified with certainty when five consecutive
fragment ions were obtained in the MS/MS analysis. Our data
(Fig. 7) indicate that Lys44 is the preferred reactive lysine in
trappin-2 and elafin, while Lys50 and Lys81 may also be targeted
by TGase for TGS1 cross-linking. Lys72 or Lys80, which MALDI-
TOF data suggested were conjugated to TGS1 (Table 1), were not
unambiguously confirmed by MS/MS. The MS/MS data
obtained for SLPI indicated that three lysines (Lys14, Lys35 and
Lys46) were TGase substrates for TGS1 conjugation (Fig. 7).
Lys46 was inferred from MS/MS fragmentation of the Cys38-
Arg58 SLPI fragment, although this latter was not retrieved by the
automatic detection of mass peaks in the MALDI-TOF analysis
(Table 1). On the other hand, several putative reactive lysines in
SLPI (Table 1) were not confirmed by MS/MS analysis and were
considered to be artefacts due to the moderate robustness of the
MALDI-TOF-derived sequence assignment compared to MS/MS
analysis. All assignments of reactive glutamines from MALDI-
TOF data for the three inhibitors were confirmed by MS/MS
analysis of DsC-conjugated peptides. The MS/MS analysis of
some peptides not detected as Dsc-derived in MALDI-TOF
analysis also enabled us to identify two other reactive glutamines in
SLPI, Gln27 and Gln70. They were identified unambiguously
from the fragmentation of Tyr21-Lys35 and semi-tryptic Cys64-
Leu72 and Arg59-Leu72 SLPI peptides. Locations of TGase-
sensitive residues in all three inhibitors are shown in Fig. 7.
Discussion
We previously showed that elafin and trappin-2 cross-linked to
various ECM proteins by the catalytic action of a tissue
transglutaminase retain their capacity to inhibit serine proteases
[8]. We have now demonstrated that the homologous SLPI
molecule can also be cross-linked to fibronectin and elastin
by tissue transglutaminase, despite its lack of the repeated
consensus sequence transglutaminase motif Gly-Gln-Asp-Pro-
Val-Lys (GQDPVK) found in trappin-2 [13]. We have also shown
that both elafin/trappin-2 and SLPI are targeted by FXIIIa. To
our knowledge, this is the first report of the transglutamination of
SLPI. It was readily cross-linked to itself or to fibronectin and
elastin by two different transglutaminases. Western blotting
analysis indicated that a Gln-containing peptide (TGS1) based
on the N-terminal sequence of fibronectin [18] and Lys-containing
peptides identified by phage display [12] that are preferred
substrates of TGase (TGS2) or FXIIIa (TGS3), interfered with the
transglutamination patterns of all three inhibitors, elafin, trappin-
2, and SLPI. This suggests that these inhibitors contain reactive
lysine and glutamine residues that are transglutaminase targets.
Because both trappin-2 and SLPI may be cross-linked to
fibronectin or elastin, we set out to answer the question of
whether these inhibitors occupied the same transglutamination
sites on these ECM proteins. The transglutaminase-catalyzed
cross-linking of SLPI to fibronectin or elastin was not modified by
excess trappin-2, while trappin-2 conjugation increased as the
trappin-2/SLPI molar ratio increased. This clearly indicates that
SLPI and trappin-2 do not compete for the same binding sites.
Although fibronectin has a restricted number of glutamine
residues that can be transglutaminated by TGase or FXIIIa
[19], the binding of the two inhibitors is not mutually exclusive.
We first tried to identify the reactive glutamine and lysine
residues involved in the cross-linking of inhibitors to fibronectin by
mass spectrometry analysis of tryptic digests of fibronectin-trappin-
2 conjugates in order to infer the positions of reactive lysines or
glutamines from the masses of tryptic fragments linked by
isopeptide bonds. But we could not accurately correlate the
experimental masses with the sequences of either the inhibitor or
fibronectin, probably because our commercial fibronectin was not
pure enough and/or there are numerous isoforms of human
fibronectin, so no unique sequence is present. Instead, we carried
out analysis by mass spectrometry of tryptic digests of TGase-
catalyzed cross-linked products involving each inhibitor and either
DsC as a lysine mimic or the glutamine-containing peptide TGS1
as transglutamination probes. MALDI-TOF analysis allowed us to
deduce most of the TGase-reactive lysine and glutamine residues
in SLPI, elafin and trappin-2 from the masses of tryptic peptides.
When tryptic peptides of inhibitors contained a number of
potentially reactive residues .1, we used MS/MS analysis to
identify unambiguously cross-linked lysine or glutamine residues
within each inhibitor. We found that three of the 5 glutamines in
SLPI, Gln17, Gln27 and Gln70, were amine acceptors, while
three of the 6 potential glutamines in trappin-2, Gln10, Gln22,
and Gln40, were targeted in trappin-2. Labeling with DsC
revealed that 3 of the 15 lysines in SLPI, Lys14, Lys 35 and Lys 46,
had incorporated the probe while the 11 lysines in trappin-2
included three, Lys 44, Lys 50 and Lys 81, that could serve as
TGase substrates. Compared to trappin-2, no difference in TGase
reactivity of elafin alone was observed which had the same reactive
Lys and Gln residues as those identified in the elafin moiety
contained in trappin-2. The five GQDPVK sequence motifs of
trappin-2 were previously found to be similar to the seminal vesicle
secretory protein SVP-1, involucrin and cornifin, all of which are
transglutaminase substrates [4]. This led to the early hypothesis
that these motifs lying mostly in the N-terminal cementoin domain
were responsible for the covalent anchoring of the elastase
inhibitor trappin-2/elafin at its site of action by transglutamination
[4]. The only data on the transglutamination sites in elafin/
trappin-2 came from a study of proteins forming the human
epidermal cornified cell envelope. Trappin-2 was found in
transglutaminase-catalyzed cross-links with the epidermal proteins
loricrin, desmoplakin, involucrin and keratin I [9]. Identification
of transglutamination sites from the amino acid composition
studies of proteinase K digests of stratum corneum extracts
revealed that most cross-links with trappin-2 involved its Gln40
and Lys44 residues, but Lys36, Lys38 and the C-terminal Gln95
Figure 4. Inhibition of neutrophil elastase and cathepsin G by inhibitors bound to fibronectin or elastin. Inhibitors (10
26 M) (SLPI, SLPI
domain 2 (SLPI2), trappin-2 and Cem-SLPI2, a fusion protein containing SLPI2 with the cementoin domain of trappin-2 fused to it N-terminus) were
first cross-linked to fibronectin or elastin in 96-well microplates by incubation with TGase or FXIIIa for 2 h at 37uC. The microplate wells were then
washed thoroughly to remove unreacted products and incubated with HNE (1 nM) or cathepsin G (2 nM) for 15 min at 37uC to form the protease-
inhibitor complexes. A fluorogenic substrate specific for each protease was then added to the wells to measure the residual enzyme activity. (A)
Inhibition of HNE by inhibitors bound to fibronectin by TGase (product release expressed as fluorescence units/time). (B, C) Residual HNE or cathepsin
G activities after incubation with inhibitors conjugated to fibronectin or elastin by TGase (B) or FXIIIa (C), calculated as the ratio of substrate hydrolysis
rates with and without inhibitor (Control). Data are represented as means 6 SEM (n=6) of residual enzymatic activity and were compared to the
control (***p#0.001, **p#0.005 and *p#0.05) using the post hoc student test.
doi:10.1371/journal.pone.0020976.g004
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sites, but we found no cross-links with Lys36, Lys38 or Gln95. This
suggests that the use of alternative reactive Lys or Gln residues
may depend on the type of transglutaminase and/or the second
substrate involved in the transamidation reaction. Surprisingly no
Gln or Lys residues contained in the GQDPVK motifs within the
cementoin domain were found to be reactive with epidermal
proteins, although these motifs were initially identified as
transglutaminase substrate sequences in trappin-2 [4]. Further-
more, those lysines in the cementoin domain that are in the same
sequence context as Lys44 (i.e included in a PVKG sequence) do
not seem to react with TGase. This implies that TGase is
Figure 5. MALDI-TOF mass spectra of peptides generated from a trypsin digest of TGase-modified inhibitors. A) Trappin-2 was
incubated with DsC plus TGase for 2 h at 37uC, reduced and alkylated, and digested with trypsin overnight. B) SLPI was labelled with the TGS1
peptide by TGase and then hydrolysed with trypsin. Those tryptic peptides that were not present in the control digest, and consequently probably
contained amino acids modified by TGase activity, are indicated by an asterisk. The experimental masses of these peptides were compared with the
masses of theoretical tryptic peptides to identify modified amino-acids (Table 1).
doi:10.1371/journal.pone.0020976.g005
Table 1. MALDI-TOF mass spectrometry analysis of tryptic peptides generated from dansylcadaverin- and PGGQQIV-labeled
trappin-2, elafin and SLPI.
[M+H]
+
Peptide fragment Amino acid sequence observed theoretical Dmass Substitution
Trappin-2 + DsC
1–14 AVTGVPVKGQDTVK 1716.94 1398.79 318.14 DsC-Q10
15–26 GRVPFNGQDPVK 1631.83 1313.69 318.13 DsC-Q22
15–32 GRVPFNGQDPVKGQVSVK 2230.19 1912.03 318.15 DsC-Q22 or Dsc-Q28
39–60 AQEPVKGPVSTKPGSCPIILIR 2665.78 2347.31* 318.46 DsC-Q40
Elafin + DsC
39–60 AQEPVKGPVSTKPGSCPIILIR 2665.68 2347.31* 318.36 DsC-Q40
SLPI + DsC
7–20 AGVCPPKKSAQCLR 1889.99 1571.81* 318.17 DsC-Q17
14–20 KSAQCLR 1180.61 862.45* 318.16 DsC-Q17
Trappin-2 + TGS1
39–60 AQEPVKGPVSTKPGSCPIILIR 3028.51 2347.31* 681.19 TGS1-K44 or TGS1-K50
73–80 DTDCPGIK 1528.77 848.38 680.39 TGS1-K80
Elafin + TGS1
39–60" AQEPVKGPVSTKPGSCPIILIR 3028.56 2347.31* 681.24 TGS1-K44 or TGS1-K50
70–95 CLKDTDCPGIKKCCEGSCGMACFVPQ 4440.48 3078.27* 1362.20 2 substitutions among TGS1-K72,
TGS1-K80, TGS1-K81
73–81 DTDCPGIKK 1713.92 1033.49 680.42 TGS1-K80 or TGS1-K81
SLPI + TGS1
1–6 SGKSFK 1333.73 653.36 680.37 TGS1-K3 or TGS1-K6
4–6 SFK 1061.56 381.21 680.35 TGS1-K6
4–20 SFKAGVCPPKKSAQCLR 2614.30 1934.00 680.29 TGS1-K6 or TGS1-K13 or TGS1-K14
7–14 AGVCPPKK 2217.05 856.47 1360.58 TGS1-K13 and TGS1-K14
7–20 AGVCPPKKSAQCLR 2252.11 1571.81* 680.29 TGS1-K13 or TG1S-K14
7–20 AGVCPPKKSAQCLR 2253.17 1571.81* 681.36 TGS1-K13 or TG1S-K14 + deamidation of Q17
7–20 AGVCPPKKSAQCLR 2875.80 1514.79* 1361.01 TGS1-K13 and TGS1-K14
21–35 YKKPECQSDWQCPGK 3157.59 1796.80 1360.78 2 substitutions among TGS1-K22,
TGS1-K23, TGS1-K35
38–58 CCPDTCGIKCLDPVDTPNPTR 3157.59 2476.06* 681.52 TGS1-K46
89–99 DLKCCMGMCGK 2014.83 1334.50* 680.33 TGS1-K91 or TGS1-K9 (oxidized methionins)
100–107 SCVSPVKA 1527.81 847.43* 680.37 TGS1-K106
Each labeled inhibitor was hydrolysed with trypsin, the resulting peptides reduced with DTT and alkylated with iodoacetamide before MALDI-TOF analysis. Putative
glutamine and lysine residues targeted by TGase were identified by the altered mass of corresponding tryptic peptides bearing DsC on Gln residues or the PGGQQIV
peptide (TGS1) on Lys residues. The release of an ammonia molecule that accompanies the formation of an isopeptide bond by TGase indicated that the expected
increase in mass of DsC-labeled Gln is +318 Da (335-17) and that of TGS1-labeled Lys is +681.38 Da (698.38-17). The theoretical masses of unsubstituted tryptic peptides
were calculated with PeptideMass software (http://www.expasy.ch/tools/peptide-mass.html).
*theoretical mass calculated assuming carbamidomethyl-Cys (carboxyamido 57.0214 g/mol).
"trappin-2 numbering.
doi:10.1371/journal.pone.0020976.t001
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2/elafin and SLPI, as it is for many other proteins [12,20,21]. Our
results provide no clear consensus sequence around reactive Gln
or Lys residues. Of the six Gln targeted in trappin-2/elafin and
SLPI, two of them were found in a QXPW motif (where X is any
amino acid and W a hydrophobic amino acid). This motif appears
to be preferred by the tissue transglutaminase 2 used in our study
[12]. Three other reactive Gln were included in a QXXW motif,
suggesting that a hydrophobic residue at +3 is important for
determining substrate selectivity. There was the same lack of a
consensus sequence around the reactive Lys residues in both
inhibitors. But the Lys35 in SLPI lies within a WQCPGK
sequence that resembles the proposed GQDPVK consensus
transglutaminase substrate sequence of the cementoin domain of
trappin-2. We were also unable to establish any correlation
between the reactivity of the Gln and Lys residues and their
accessibilty in the 3D structure of SLPI and the elafin moiety of
trappin-2 (data not shown), in agreement with previous findings
suggesting that other structural determinants in the vicinity of
reactive residues are important [20,21].
Because trappin-2 appeared to be a better TGase substrate
than SLPI with all substrates tested, including involucrin (data
not shown), we examined the capacities of the two inhibitors to
compete in the transglutaminase-catalysed binding to various
ECM proteins. Experiments with fibronectin, which has eight
TGase binding sites per intact molecule (four per 220 kDa
monomer) [19], showed that SLPI and trappin-2 were not
competing with each other; the same was true for binding to
elastin. Our findings that SLPI may be cross-linked to elastin by a
transglutaminase-mediated process may explain why this inhibitor
was found to be associated with elastin fibers in the skin [15] and
in the parenchymal matrix of the lung alveolar walls [14] by a
hitherto unknown mechanism. We do not know whether trappin-2
is also specifically conjugated to elastin in vivo, although there is
evidence that it can be detected as high-molecular weight forms in
psoriasis skin or lung tissues, as a probable consequence of
tranglutaminase-mediated conjugation [4,6]. As previously sug-
gested [4,7,8], the obvious biological function of the transgluta-
minase-catalysed covalent linking of trappin-2/elafin to ECM
proteins is to protect them from degradation by neutrophil serine
proteases, so helping maintain tissue integrity during inflammation
and/or tissue remodelling. We have shown that SLPI covalently
bound to fibronectin or elastin also retains its ability to inhibit its
target proteases (HNE and CatG). Hence, conjugated SLPI,
together with trappin-2/elafin, may be important for preventing
the breakdown of elastin and other structural proteins at
inflammatory sites. Both SLPI and trappin-2 have anti-microbial
activities (reviewed in [2]), but we do not yet know whether there is
a link between their transglutamination and the recently described
mechanism of pathogen entrapment by transglutaminase [22].
SLPI and trappin-2/elafin are not the only protease inhibitors
targeted by transglutaminases. Three members of the cystatin
superfamily of cysteine protease inhibitors, cystatin alpha [23],
cystatin M/E [24] and cystatin CRES [25], two serpins, PAI-2
[26] and a2-antiplasmin [27], a2-macroglobulin [28] and
Streptomyces subtilisin and TAMEP inhibitor (SSTI) [29] are all
transglutaminase substrates. The major role of all these cross-
linked inhibitors seems to be the regulation of protease activity,
although it is always possible that these conjugated inhibitors could
have other, so far unidentified, biological functions.
We have also shown that the fusion protein (Cem-SLPI2)
containing the cementoin domain of trappin-2 linked to SLPI
Figure 6. MS-MS mass spectrometry analysis of the tryptic peptides generated from DsC- or TGS1-labeled inhibitors. Certain tryptic
peptides were further fragmentated and analyzed by MS-MS to unambiguously identify the glutamine or lysine residues in trappin-2, elafin or SLPI
targeted by TGase. Modified glutamine and lysine were identified based on their altered molecular mass due to Dsc and TGS1 cross-linking by TGase
respectively, while amino acid sequences were obtained from the peptide fragmentation patterns. The figure shows two representative MS-MS
spectra, one for a peptide with a m/z of 1115.40 (2
+) from the tryptic digest of DsC-labelled trappin-2 (A) and the second with a m/z of 1009.81 (3
+)
found after tryptic hydrolysis of elafin cross-linked to TGS1 peptide. The fragmentation pattern with experimentally-assigned ions is shown above
each spectrum. For the sake of clarity, not all peaks of daughter ions were labelled on each spectrum.
doi:10.1371/journal.pone.0020976.g006
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alone. This suggests that the cementoin domain has potential for
biotechnological applications, such as the transglutaminase-
catalysed immobilization of biologically active therapeutic proteins




Human neutrophil elastase (HNE) (EC 3.4.21.37), was obtained
from Biocentrum (Krakow, Poland), human proteinase 3 (Pr3) (EC
3.4.21.76) was from Athens Research and Technology (Athens,
USA) and cathepsin G (CatG) (EC 3.4.21.20) was from MP
Biomedicals (Vannes, France). Fluorogenic substrates specific for
each neutrophil proteinase were custom-synthesized by Gencust
Europe (Dudelange, Luxembourg). Human fibronectin, bovine
neck elastin, dansylcadaverine (DsC) and guinea pig liver
transglutaminase (TGase) (EC 2.3.2.13) were from Sigma-Aldrich
(St Quentin Fallavier, France) and factor XIIIa was from
Kordia (Leiden, The Netherlands). Transglutaminase peptide
substrates PGGQQIV (TGS1), HQSYVDPWMLDH (TGS2) and
DQMMLPWPAVAL (TGS3) were supplied by Genosphere
Biotechnologies (Paris, France). Anti-SLPI antibodies were from
Tebu-Bio (Le Perray en Yvelines, France). Rabbit anti-trappin-2
antibodies were prepared in house using recombinant trappin-2 as
antigen. All other reagents were of analytical grade.
Construction, expression and purification of SLPI, SLPI2
and Cem-SLPI2
Wild type SLPI, SLPI domain 2 (SLPI2) and Cem-SLPI2 were
produced as tag-free recombinant proteins in the Pichia pastoris
Figure 7. Location of TGase-reactive Gln and Lys residues in SLPI, trappin-2 and elafin. Structural organization of SLPI (A) with its two
elafin-like domains, trappin-2 (B) and elafin (C). The amino acid sequence of each inhibitor is shown below each structure. The disulfide bond
topology (plain lines) and the inhibitory loop (half black disc) of each inhibitor are also shown. Arrows show the TGase-reactive Gln residues in SLPI
(17, 27, 70) and trappin-2 (10, 22, 40) and the reactive Lys residues in SLPI (14, 35, 46) and trappin-2 (44, 50, 81). The reactive residues in elafin
(trappin-2 numbering) were the same as those in the elafin moiety of trappin-2. Asterisks above the amino acid sequence denote the location of the
reactive residues in each inhibitor.
doi:10.1371/journal.pone.0020976.g007
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binant elafin and trappin-2 [30] using a cDNA encoding the
full-length SLPI protein (a gift from Dr. M. Kemme, University
of Darmstadt, Germany). The full length SLPI cDNA was
amplified by PCR using SLPIFor (59-CGACTCGAGAAAA-
GATCTGGAAAGTCCTTCAAAGC-39) and SLPI2rev (59-CGA-
GCGGCCGCGGAATCAAGCTTTCACAGG-39) primers, and
SLPI domain 2 (SLPI2) cDNA was amplified with SLPI2For (59-
CGACTCGAGAAAAGGGATCCTGTTGACACCCC-39) and
SLPI2Rev primers (MWG Biotech, Villebon sur Yvette, France).
Cem-SLPI2 cDNA was generated using the trappin-2 cDNA
and the cDNA encoding the SLPI full-length protein as tem-
plates. The cementoin domain of trappin-2 was amplified using
CemFor (CGACTCGAGAAAAGAGCTGTCACGGGAGTTCC-
T-39) and Rev (59-TGGGGTGTCAACAGGATCTTTGACTT-
TATCTTGACCTTTA-39) as primers. The cDNA encoding the
SLPI2 domain was amplified using For (59-TAAAGGTCAAGT-
CAAAGATCCTGTGACCCCA-39) and SLPI2Rev as primers.
Full length chimera cDNA was obtained by fusing the two PCR
products by the standard procedure of Higuchi et al. [31]. All the
PCR reactions were done with Taq/Pwo DNA polymerase
(Expand High Fidelity system) from Roche (Meylan, France).
The cDNAs were cloned into the pPIC9 vector (Invitrogen,
Groningen, The Netherlands) and electroporated into Pichia
pastoris yeast strain GS115 (his4) competent cells (Invitrogen,
Carlsbad, CA, USA). The inhibitors were then expressed and
purified by cation exchange chromatography by the procedures
used for elafin and trappin-2 [30]. The purified SLPI, SLPI2
and Cem-SLPI2 molecules migrated as single bands at 12 kDa,
6 kDa and 10 kDa in reducing SDS/PAGE gel, indicating their
homogeneity.
Transglutamination assays
TGase-/FXIIIa-mediated incorporation of DsC and
peptides into elafin, trappin-2 and SLPI. Cross-linked
complexes were formed by incubating elafin, trappin-2 and SLPI
(each 1.2 10
25 M) with or without DsC (2 mM) or peptides TGS1,
TGS2, TGS3 (2.4 mM) and TGase (1.25610
27 M) or FXIIIa
(2610
26 M) in 50 mM Tris-HCl buffer, pH 7.5, 2 mM CaCl2,
0.1 mM dithiothreitol (DTT) for 1 h at 37uC. Samples were boiled
and the peptides separated on high resolution Tris-Tricine SDS-
PAGE gels [32] and the separated peptides transferred to
nitrocellulose membranes (GE Healthcare, Orsay, France).
Membrane free sites were blocked by incubation with PBS
containing 5% skim milk for 1 h at room temperature. Elafin and
trappin-2 were detected by incubation with our rabbit anti-trappin-
2 (1/10000) antibodies and SLPI (1/2000) overnight at 4uC
followed by appropriate HRP-coupled secondary antibodies
(Sigma-Aldrich, St Quentin Fallavier, France). The washing
buffer was PBS containing 1% Tween 20.
Competition for the TGase-/FXIIIa-catalysed cross-
linking of SLPI and trappin-2 to the extracellular matrix
proteins fibronectin and elastin. Fixed concentrations of
SLPI (3610
26 M) and increasing concentrations of trappin-2
(3610
27 Mt o7 610
26 M) were mixed with fibronectin (3 mg) or
elastin (5 mg) and incubated with TGase (1.25610
27 M) or FXIIIa
(1610
26 M) in 50 mM Tris-HCl buffer, pH 7.5, 2 mM CaCl2,
0.1 mM DTT for 2 h at 37uC. The samples were then boiled in
denaturing buffer and the cross-linked complexes with fibronectin
or elastin separated on 10% Tris-Glycine SDS-PAGE. The
separated proteins were transferred to nitrocellulose membranes
and the free sites on the membranes were blocked as described
above. Trappin-2 was detected by incubation with our rabbit anti-
trappin-2 (1/5000) antibodies, and anti-SLPI (1/1000) overnight
at 4uC, followed by the appropriate HRP-coupled secondary
antibodies (Sigma Aldrich, St Quentin Fallavier, France).
Kinetic studies with soluble neutrophil proteases. The
equilibrium dissociation constant Ki for the interaction of SLPI2
and Cem-SLPI2 with HNE or CatG were determined by adding
substrate to an equilibrium mixture of protease and inhibitor in
50 mM Hepes buffer, pH 7.4, 150 mM NaCl for HNE and in
50 mM Hepes buffer, pH 7.4, 50 mM NaCl for CatG at 37uC.
Residual enzyme activities were measured using the specific
fluorogenic substrates Abz-APEEIMRRQ-EDDnp for HNE and
Abz-TPFSGQ-EDDnp for CatG (10 mM final). Substrate-
independent Ki values were determined from experimental data
as previously described [10].
Inhibitory properties of recombinant inhibitors cross-
linked to fibronectin and elastin by tissue transglutaminase
and factor XIIIa. ELISA microplates (96-well, Fluoronunc
Maxisorp plates) were coated (2 mg/well) with fibronectin or
elastin in 0.1 M sodium carbonate buffer (pH 9.5) by incubation
overnight at 4uC. The coated plates were washed with 25 mM
potassium phosphate buffer pH 7.4, 0.15 M NaCl and free sites
were blocked by incubation in 50 mM Tris, 150 mM NaCl, 2%
Tween 20 for 1 h at 37uC. Inhibitors (10
26 M) were incubated in
these wells with TGase (1.25610
27 M) or FXIIIa (10
26 M) in
50 mM Tris-HCl buffer, pH 7.5, 2 mM CaCl2, 0.1 mM DTT for
2 h at 37uC to form cross-linked complexes with fibronectin or
elastin. The plates were again extensively washed with the same
buffer as above and human elastase (10
29 M), proteinase 3
(2610
29 M), or cathepsin G (2610
29 M) in appropriate buffers
was added and incubated for 15 min at 37uC to form protease-
inhibitor complexes. Residual protease activity was then measured
with the appropriate fluorogenic substrate (10 mM) and a
SPECTRAmax Gemini microplate reader (Molecular Devices
France, St Gre ´goire, France). Data are represented as means of
residual enzymatic activity 6SEM and were analyzed using the
analysis of the variance (ANOVA) followed by post hoc Student-t
test (***p#0.001, **p#0.005 and *p#0.05).
Mass spectrometry analysis
MALDI-TOF mass spectrometry on whole proteins. All
mass spectra were generated on a M@LDI LR (Waters,
Manchester, UK) MALDI-TOF mass spectrometer, operating in
positive linear mode. Aliquots (0.5 mL) of sample and matrix (1:2,
v/v) (20 mg/ml sinapinic acid) in 50% acetonitrile, 0.1% TFA
were loaded on the target using the dried droplet method. External
mass calibration was performed with a mixture containing Glu-
fibrinopeptide B, ACTH (18–39 clip), insulin, ubiquitin (all at
1 pmol/mL), cytochrome C (2 pmol/mL), myoglobin (4 pmol/mL)
and trypsinogen (8 pmol/mL). Mass spectra were recorded in the
mass range 1000–30000 m/z, acquiring 10 shots per spectrum at a
laser firing rate of 10 Hz. Data were processed using MassLynx
TM
4.0 software. The background was subtracted from the spectrum
from each sample well using a polynomial order of 10% below the
curve and smoothed with the minimum peak width at half height
set to 15 channels. Two smoothes were performed using the
Savitzky Golay algorithm. Internal mass calibration was
performed with Lock Mass option at m/z 9930.78 for trappin-2,
6000.26 for elafin and 11711.05 for SLPI. All spectra were
processed using the same parameters.
MALDI-TOF peptide mass fingerprint. Each sample were
reduced with 5 mM dithiothreitol, alkylated with 12.5 mM
iodoacetamide and incubated overnight at 37uC with 0.1 mg
bovine trypsin (Roche, Paris). The tryptic digests were acidified
with 1 mL 5% formic acid in water and sonicated for 10 min. The
matrix used was 5 mg/mL a-cyano-4-hydroxycinnamic acid in
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ether18-C6. The sample and the matrix (1:1, v/v) were loaded
onto the target using the dried droplet method. MALDI-TOF
spectra of the peptides were obtained with M@LDI L/R P/N
mass spectrometer (Waters, Manchester UK) in the 500–4500 m/
z mass range. The analyses were performed in positive ion
reflectror mode acquiring 10 shots per spectrum at a laser firing
rate of 5 Hz, with an accelerating voltage of 15000 V. The
resulting spectra were calibrated externally using the [M+H]
+ ions
from a bovine serum albumin digest. Raw data files were
converted to mzXML with ProteinLynx Global server 2.2
software (Waters, Manchester, UK). MS data were matched
automatically to a database containing the trappin-2, elafin and
SLPI protein sequences using the Peptide Mass Fingerprint search
option of the MASCOT server software (Matrix Science, UK).
Enzyme specificity was set to trypsin with 5 missed cleavages
using carbamidomethylcysteine (+57 Da), methionine oxidation
(+16 Da), deamidated N/Q (+1) and Dsc (+318 Da) or PQQ-
GGIV (+680 Da) as variable modifications. The tolerance of the
ions was set to 150 ppm.
NanoLC-MS/MS. The Ettan MDLC controlled by UNIC-
ORN
TM software (GE Healthcare, Germany) was used to desalt
and separate tryptic peptides prior to online MS and MS/MS
analyses. Aliquots (4 mL) of digested sample were mixed with
10 mL 1% formic acid and 10 mL of these mixes were injected
using the mL-pickup mode. Each sample was automatically
desalted and concentrated using a Zorbax 300-SB C18 trap
column, 300 mm i.d65 mm (Agilent Technologies, Germany).
Peptide were separated on a Zorbax 300-SB C18 column, 75 mm
i.d6150 mm (Agilent Technologies, Germany). Buffer A was 0.1%
formic acid in water and buffer B was 0.1% formic acid in 84%
aqueous acetonitrile. Peptides were eluted with a 15–55% gradient
of buffer B at a flow rate of 350 nL/min for 60 min. The peptides
were analysed online with an LTQ Linear Ion Trap Mass
Spectrometer (Thermo Electron, US) using a Thermo Electron
Dynamic Nanospray Probe interface. Ionisation was performed
(1.8–2.1 kV) with liquid junction and uncoated fused-silica
nanoESI 25 mm i.d emitters (New objective, Woburn, USA).
The ion transfer capillary was set to 200uC. Each scan
cycle consisted of one full scan mass spectrum (m/z 500–2000)
collected in enhanced mode followed by three MS/MS events
in centroid mode (Qz=0.25, Activation Time=40 ms). The
isolation width for CID spectra (MS2) was 2 m/z units and
the normalized collision energy was 40%. Dynamic exclusion
was activated for 30 s with a repeat count of 1. Raw data files were
converted to mzXML with Bioworks 3.3.1
TM software (Thermo
Fischer Scientific, San Jose, CA). The peptide and fragment
masses obtained were matched automatically with a database
containing the trappin-2, elafin and SLPI protein sequences
and using the MASCOT Daemon v2.2.2 (Matrix Science,
UK) search option of the MASCOT server software. Enzyme
specificity was set to semitrypsin with 5 missed cleavages
using carbamidomethylcysteine (+57 Da), methionine oxidation
(+16 Da), deamidated N/Q (+1) and Dsc (+318) or PQQGGIV
(+680) as variable modifications. The tolerance of the ions was set
to 1.4 Da for parent and 1.0 Da for fragment ion matches. Hits
with a P value,0.05 were manually verified and peptides were
considered positively identified with 5 consecutive fragment ions.
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